[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.238.190.122. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
September 19, 2019

100 Years of JAMA Neurology and the Journey Back to the Beginning

Author Affiliations
  • 1Department of Neurology, University of California, San Francisco
  • 2Editor, JAMA Neurology
JAMA Neurol. 2019;76(11):1279-1280. doi:10.1001/jamaneurol.2019.3056

We would like to take a moment to recognize the 100th anniversary of JAMA Neurology, which was first launched by the American Medical Association in 1919 as the Archives of Neurology and Psychiatry. In the immediate aftermath of World War I, the table of contents of the first issue (Figure) reflected a medical community dealing with the realities of acute neurologic and psychiatric injuries, as well as lingering conditions, in those who returned from the battlefront. Articles advancing treatments of “so-called ‘shell shock’”1 and “war neuroses”2,3 sit comfortably next to a piece on the histogenesis of multiple sclerosis.4 In the issues that followed over the next few months, observations ranged from the neurological manifestations of and new therapies for syphilis5,6 to attempts to treat what was likely schizophrenia using injections of sodium chloride,7 as well as detailed descriptions of wartime spinal cord and peripheral nerve injuries.8,9 The first volume’s issues were groundbreaking and robust for the time, with great relevance to the practicing physician—certainly an impressive accomplishment for such a fledgling journal.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×